What happened
Valion Bio, Inc. (NASDAQ: VBIO) said Velocity Bioworks completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform on October 15, 2026. Velocity Bioworks is Valion's wholly owned biologics contract development and manufacturing organization subsidiary. Valion said BioScan-NMR is being developed as a new process analytical technology for biologics manufacturing. The evaluation produced data that support continuous, real-time, non-invasive bioprocess monitoring of cell size, density, viability and phenotype in bioreactors.
The company said the technology is built for closed-system measurements. It could reduce the need for routine offline sampling. Valion said the initial results are encouraging. The platform signal showed a strong correlation with optical density at 600 nm, or OD600. Valion also said the results suggest nuclear magnetic resonance measurements could track microbial growth during fermentation.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Press release date | October 15, 2026 | Press release, dated October 15, 2026 | |
| Time to milestone | less than six months | Press release, dated October 15, 2026 | |
| Optical density benchmark | 600 nm | Press release, dated October 15, 2026 |
Read more: Valion Bio (VBIO) stock analysis and investment case
Why it matters
OptimistFi's case is that VBIO is only attractive as a financed biotech option, so progress on assets matters as much as cash runway. This filing adds an early technical update for Velocity Bioworks. The signal also tracked closely with OD600, which is a common measure of cell density. The release says the platform could reduce reliance on routine invasive sampling and sample processing.
The short gap between the rights deal and this test suggests the partnership moved quickly from agreement to proof of concept.
Valion said innovation and differentiation are becoming more important in the CDMO industry, and it cast this milestone as part of that strategy. The company also said the project is still an early-stage proof of concept. Later work must confirm that it can reliably monitor additional critical process attributes.
Browse: stock research on every company OptimistFi covers
What's next
Velocity Bioworks plans to use the results to guide later development work. Those next steps include testing the closed-system and continuous monitoring features. Valion said it looks forward to full implementation of the PAT system at Velocity Bioworks. The release says that if later development shows reliable monitoring of additional critical process attributes in a closed system, BioScan-NMR could become an enabling technology for more data-rich, responsive and efficient bioprocessing.
If it stays a proof of concept, this filing remains an early technical step rather than a commercial one.
More from OptimistFi
- VBIO stock: the Valion Bio thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K — Current report announcing the press release and identifying Valion Bio, Inc. as the registrant.
- Press release, dated October 15, 2026 — Exhibit 99.1 press release describing the BioScan-NMR feasibility milestone.
Read the full OptimistFi thesis on Valion Bio, Inc.: https://optimistfi.com/stocks/VBIO
See what would break the Valion Bio, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Valion Bio, Inc. investment case, its status and the next test to watch live on the Valion Bio, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
